Some time ago, I received a private message from a liver friend, she said that she is now very badly controlled by the virus, and she pessimistically believes that liver cancer is her ultimate destination...
I persuaded for a long time, I don't know if she listened, I hope she can cheer up, but also hope that liver friends with this pessimism do not think wildly!
For hepatitis B patients, the most worrying question is whether they will get liver cancer and embark on the road of no return of "hepatitis B- cirrhosis - liver cancer".
The mainland is a big country of hepatitis B, 40% of chronic hepatitis B patients will progress to cirrhosis and liver cancer, but this does not mean that this proportion will not decrease, I believe that through our own and the progress of medical science and technology, our final destination will never be liver cancer!
What is accelerating the progression of chronic hepatitis B?
1. Age
The older you are, the more likely you are to develop hepatitis B.
Clinically, it is generally believed that more than 40 years old is more dangerous.
In addition, age and etiology are factors that affect the progression of liver disease to cirrhosis.
2. Gender
The study found that men were more likely to develop than women.
3. Family history of liver cancer
Those with a family history of liver cancer are more likely to progress.
Many patients in Asia have a familial history of liver cancer, so Asians are more likely to develop liver cancer and cirrhosis.
4. Poor lifestyle
Smoking, alcoholism, staying up late, overwork, etc.
5. Environmental factors
In some places, the living environment is not good, and food and water sources are susceptible to pollution, which is also a risk factor.
6. Risk factors for virus-related hepatitis B disease
These include high viral load, hepatitis B virus genotype, co-infection with hepatitis B and C, viral mutations, etc.
If the controllable risk factors can be controlled, early intervention can be carried out for chronic hepatitis B, so that the disease can develop in a good direction and reduce the probability of liver cancer.
How to scientifically monitor the progression of chronic hepatitis B?
In fact, getting hepatitis B is not terrible, the terrible thing is to lose the confidence to adhere to treatment and normal life.
Only a small percentage of patients with chronic hepatitis B will develop cirrhosis, and only about 10% of patients with cirrhosis will develop primary liver cancer.
The development of chronic hepatitis B into cirrhosis and even liver cancer generally requires a long process, but this process may be quiet and quiet, and no physical examination may not know where hepatitis B has progressed.
Many liver friends go to the hospital because they feel unwell, and 80% of the liver cancer found at this time is advanced liver cancer.
This has a lot to do with the fact that patients don't pay attention to regular physical examinations.
It is understood that the University Hospital of Tokyo in Japan has a patient management system, which records the data of all patients, of which about 8,000 hepatitis B patients, through follow-up management, can find about 80% of early liver cancer.
For hepatitis B patients, long-term monitoring and management should be carried out, and ultra-early screening of liver cancer based on liquid biopsy technology should be done every year for liver function, hepatitis B five, alpha-fetoprotein (AFP), liver ultrasound, and liquid biopsy technology.
Panshenggan pre-liver cancer ultra-early screening is a more cutting-edge liver cancer early screening method, which is based on cfDNA liquid biopsy technology, providing a reliable and easy solution for early detection, early diagnosis and early treatment of liver cancer.
In 2020, the original research liver cancer early screening technology used by Gan Pre was recognized as a "breakthrough medical device" by the US Food and Drug Administration (FDA), which marked that Gan Pre was a successful early screening technical service independently developed by China in the world.
Only 10ml of blood is drawn, and the three major indicators in the blood: protein expression + gene mutation + gene methylation level are multi-dimensional detection, looking for weak early liver cancer signals, which can help liver friends find liver cancer in the asymptomatic period.
The "Specification for the Diagnosis and Treatment of Primary Liver Cancer (2019 Edition)" points out that specific mutant DNA fragments released from tumors into peripheral blood can reflect the genomic information of tumors, which can be used for early diagnosis of liver cancer, monitoring tumor progression and response to treatment. The sensitivity and specificity of early diagnosis of liver cancer are better than those of serum AFP.
Early detection and diagnosis, and then through active and effective treatment, the patient's cure rate will be greatly improved, and the cost of treatment will be as low as tens of thousands of yuan, which is a world of difference compared with the treatment cost of millions in the middle and late stages.
Not only the technology is cutting-edge, but the service is more in place. The full-dimensional health management service provides different health management protection for testers who test negative or positive.
Coverage for negative testers:
· Insurance protection, up to a maximum of 100,000 yuan
· Free 1-on-1 health consultant report interpretation
Positive Tester Coverage:
· Worth 3,000 yuan of image green pass and diagnosis and treatment services
· Valued at 1500 yuan enhanced CT or NUCLEAR magnetic quick loss
· Confirmed patients were given 825 genetic tests worth 19,800 yuan for accurate diagnosis and treatment of liver cancer
The service process is clear, safe and intimate. There is an SMS notification at each step of the test, and the test report can be obtained within 10 working days after receiving the sample. It can be said that gan pre-liver cancer ultra-early screening is a managed, systematic liver health management service.
Come to Jingdong [Panshengzi Gene Testing Flagship Store] to learn more details about the ultra-early screening of Gan pre-liver cancer.
Bring your health home!